Tag Archives: drug pricing

2 Comments

Iris Gorfinkel is a General Practitioner, and Founder and Principal Investigator at PrimeHealth Clinical Research in Toronto, Ontario.

 

On July 10, 2018 Health Canada issued a recall of several products containing the blood pressure lowering drug, valsartan. This came in response to a disclosure from its Chinese manufacturer that the drug had been contaminated with a known carcinogen. A massive effort to contact patients to stop the affected drug lots, and to replace it with an alternative, ensued. Few clinicians had been even remotely aware that ...continue reading

1 Comment

Jacalyn Duffin is a hematologist and historian who holds the Hannah Chair in the History of Medicine at Queen’s University

 

The sixth full year of the global generic drug shortage has drawn to a close. We Canadians can look back and marvel at how little we still know about the problem. Generic drug shortages do not get anything like the attention paid to the fraught relationship between the federal government and the provinces over a renewed health accord. They are also obscured by concerns over brand-name, on-patent pharmaceuticals, such as the shocking price hikes that occurred overnight last February when Martin Shkreli raised the price of Daraprim from $13.50 to $750, or when Valeant upped the price for a month’s supply of two drugs for Wilson’s disease to more than $25,000. Yet, looking back over 2016, Canada has reported shortages of reliable generic drugs for epilepsy, bladder cancer, psychosis, syphilis, asthma, and kits for treating overdose.  ...continue reading